SecurityGLKQY / Glenmark Pharmaceuticals (006698755)
Institutional Owners0

Institutional Stock Ownership and Shareholders()

GLKQY / Glenmark Pharmaceuticals Institutional Ownership

Glenmark Pharmaceuticals (OTC:GLKQY) has 0 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). Largest shareholders include .
Glenmark Pharmaceuticals (OTC:GLKQY) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Embed this chart! (it updates automatically)
<a href="https://fintel.io/so/us/glkqy"><img src="https://images.fintel.io/us-glkqy-so.png" alt="GLKQY / Glenmark Pharmaceuticals Institutional Ownership"><a>

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

Glenmark shares jump over 2%

2018-07-17 thehindubusinessline
Shares of Glenmark Pharmaceuticals climbed as much as 2.1 per cent to Rs 563 as the company has received final approval from the US health regulator for Colesevelam Hydrochloride for oral suspension, used to lower cholesterol levels in the blood.

Glenmark Pharmaceuticals gets USFDA nod for cholesterol lowering drug

2018-07-17 moneycontrol
Glenmark Pharmaceuticals has received final approval from the US health regulator for Colesevelam Hydrochloride for oral suspension, used to lower cholesterol levels in the blood. The approval has been granted by the United States Food and Drug Administration (USFDA) in the strengths of 1.875 grams/packet and 3.75 grams/packet, the company said in a BSE filing today.

Glenmark Pharma gains 1% on USFDA nod; acquires 100% in Zorg

2018-07-17 moneycontrol
Shares of Glenmark Pharma added 1.5 percent in the opening trade on Tuesday as company received final approval from USFDA for Colesevelam Hydrochloride.

Glenmark falls 2.4% as CCI slaps Rs 47 cr penalty

2018-07-16 thehindubusinessline
Shares of Glenmark Pharmaceuticals fell as much as 2.4 per cent to Rs 551.50, their lowest since June 8, on CCI penalty.

Glenmark launches Akynzeo in India under licensing pact with Helsinn

2018-07-12 moneycontrol
Glenmark Pharmaceuticals today launched Akynzeo, a drug used for prevention chemotherapy-induced nausea and vomiting, in India and Nepal under an exclusive licensing pact with Swiss pharma group, Helsinn. Akynzeo is an oral fixed combination of netupitant 300 mg and palonosetron 0.5 mg. It is administered in a single capsule and offers 5-day prophylaxis from of both acute and delayed phases of chemotherapy-induced nausea and vomiting (CINV).

CUSIP: 006698755